A couple of years ago, Pfizer passed on an option to buy out AM-Pharma and its recombinant human alkaline phosphatase for kidney failure on the heels of some mixed Phase II data. Now, the program has attracted a new partner — and an approval could mean a big payout for AM-Pharma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,